22853 Investors following Biocon. Share this News with them.
0
Like this story, share it with millions of investors on M3
Cipla dethrones Ranbaxy to become local retail major
Cipla is up 1.86% in today’s trades on the NSE after it edged past Ranbaxy Laboratories to become the No 1 retail company in the domestic pharma space. These figures were thrown up by a survey carried out by ORG.
Cipla is up 1.86% in today's trade on the NSE after it edged past Ranbaxy Laboratories to become the No 1 retail company in the domestic pharma space. These figures were thrown up by a survey carried out by ORG. For the 12-month period ended May, it has raced ahead of Ranbaxy. However, Ranbaxy, which is up 1.01%, is clearly the market leader, in terms of domestic market share, if one takes into consideration FY07.
For the year ended May 2007, Cipla is the market leader with a 5.05% market share followed closely by Ranbaxy at 5.04%. Glaxo SmithKline came in a distant third with a 5% market share. For May, Cipla's market share was 5.05% against 4.82% for Ranbaxy. It may be interesting to note that on a monthly basis, Cipla has been the market leader for the last three months.
Cipla, Ranbaxy, and GSK have been the frontrunners for the top slot for some years now. Ranbaxy has been the dominant player, leading the market since July last year. GSK briefly held the top position earlier this year but Ranbaxy regained the numero uno position in March for the 12-month period, only to be replaced by Cipla in May.
In revenue terms, Cipla's revenue from domestic market is about Rs 2 crore more than Ranbaxy or about 0.1%. According to ORG figures, the market shares of majors such as Cipla, Ranbaxy, and GSK have either remained stable or have marginally gone down from around 5% over the past few years.
For the year ended May 2007, Cipla is the market leader with a 5.05% market share followed closely by Ranbaxy at 5.04%. 
